의료기기 이야기

The FDA Oncology Center of Excellence (OCE) in conjunction with the European Medicines Agency (EMA) will host a Conversations on Cancer public panel discussion October 19, 2023, addressing the experience of living with metastatic breast cancer. The panel will feature speakers with a range of perspectives on breast cancer and, for the first time, will be an international collaboration with our co..

This guidance document provides Food and Drug Administration’s (FDA’s or the Agency’s) recommendations on testing to assess the safety and compatibility of medical devices in the Magnetic Resonance (MR) Environment and the recommended format for Magnetic Resonance Imaging (MRI) Safety Information in medical device labeling. This guidance applies to all medical devices that might be used in the M..

This guidance document provides a detailed description of the information that should be included in a premarket notification for a magnetic resonance diagnostic device (MRDD). This document is intended to be used in conjunction with information regarding the content and format of a 510(k) premarket notification. The approach outlined in this guidance document is intended to facilitate the timel..

Each year, the Center for Devices and Radiological Health (CDRH) posts two lists of guidance documents that it intends to publish during the fiscal year. These lists are: The A-list: A list of prioritized guidance documents that the Agency intends to publish during the fiscal year. The B-list: a list of guidance documents that the Agency intends to publish as resources permit during the fiscal y..

This is a list of nucleic acid-based tests that have been cleared or approved by the Center for Devices and Radiological Health. These tests analyze variations in the sequence, structure, or expression of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in order to diagnose disease or medical conditions, infection with an identifiable pathogen, or determine genetic carrier status. Nucleic ..

FDA updated of the list of cleared or approved companion diagnostic devices (in vitro and imaging tools). - Device: CRCDx RAS mutation detection assay kit - Generic name: somatic gene mutation detection system - Applicant: EntroGen, Inc - PMA number: P220005 - Approval order statement Approval for the CRCdx® RAS Mutation Detection Kit. The device is a qualitative real-time PCR in vitro diagnosti..

미 FDA에서 510(k) 허가를 위한 서류 제출방식 가이던스를 발간하였다. ▶ 적용시점 FDA is identifying October 1, 2023 as the date on which the 510(k) electronic submission requirements will take effect. ▶ Scope This guidance describes the technical standards associated with preparation of the electronic submission template for 510(k)s that enable submission of the 510(k) electronic submission solely in electronic format. The el..

▶ FDA에서 사이버보안관련 가이드라인을 발표하면서 자주하는 질문에 대해 같이 안내함 Cybersecurity in Medical Devices Frequently Asked Questions (FAQs) | FDA Cybersecurity in Medical Devices Frequently Asked Questions (FAQs) Answers to frequently asked questions about cybersecurity in medical devices. www.fda.gov

▶ FDA에서 의료기기 사이버보안과 관련된 가이드라인을 발표함 ▶ 적용해야 되는 인허가 프로세스: 510(k), De Novo, PMA, PDP, IDE, HDE, BLA, IND ▶ 적용제품: Software, Hardware and firmware ▶ 생산 전, 생산 후 단계를 고려하여 품질경영시스템 (QSR)에도 반영 되어야 함 ▶ 인허가를 위해 필요한 서류와 점검 단계를 설명 Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions | FDA Cybersecurity: Quality System Considerations and Premarket Submissions This..

미국 FDA (식품의약품안전처) 내부 CDRH 부서에서 국제규격과 미국 내부 규정과의 조화 (harmonization)를 위한 계획안을 발표하였다 (draft strategic plan). ▶ Mission It is CDRH's mission to protect and promote the US public health. From an international perspective, this means integrating the US into the international medical device ecosystem. To do so, we develop and foster relationships with other regulatory authorities and strategic partners..